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Abstract 
bi 1985, prostaglandins of the E and F series have been found to have 
effects on the contractility of the uterine arteries (UAs) and its branches in vitro 
(Maigaard S et al.，1985). The prostaglandin Ei analogue, gemeprost has been 
studied by Joupplia P et al. in 1994. The impact ofgemeprost on the uterine artery 
(UA) and the fetal heart rate (FHR) during the first trimester pregnancy were 
studied. They found that vaginal application of gemeprost in early pregnancy 
increases the vascular resistance ofUAs and the effect is not affected by parity or 
gestation and the change is similar in both UAs. Otherwise some investigators 
have reported that gemeprost increases the median value of pulsatility index in the 
dominant uterine artery in the first trimester and can induce fetal bradycardia and 
sometimes demise (Valentin L et al., 1995). 
Misoprostol is a prostaglandin Ei analogue which was originally developed 
as a prophylactic agent against peptic ulceration in patients taking non steroidal 
anti-inflammatoiy drugs (NSAID). Misoprostol has been used in Obstetrics and 
Gynecology (0&G) since the late 1980s. It has been used as an aboitifacient 
agent in first trimester (Baird DT et al.，1992) and second trimester (BugaUio A et 
al., 1993) with or without mifepristone. More recently, its use in late pregnancy to 
induce labour has been reported (Margulies M et aL, 1992). 
As misoprostol is as effective as gemeprost and is more convenient to use, it 
has been a substitute for gemeprost in therapeutic abortion. Misoprostol is also 
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being used in the second and third trimesters ofpregnancy where fetal compromise 
is a potential hazard. However, there has been little research into the effect of 
misoprostol on the utero-placental circulation and its potential impact on the fetus. 
The aim of this thesis was to assess the effects of misoprostol on the 
resistance ofthe main uterine arteries and on the fetus in normal early pregnancy. 
This thesis tests the following hypotheses: 
Hypothesis 1 
That misoprostol (200^ig) increases the resistance of the main uterine 
arteries in normal early pregnancy. 
Result 
Misoprostol significantly increased the resistance indices including 
pulsatility index (PI) and systolic velocity to diastolic velocity ratio (S/D ratio) of 
the main uterine arteries (both P<0.01). The change was not affected by the 
presence of abdominal pain. 
) 
Conclusion: 




An oral dose of 200vig of misoprostol affects the fetal heart rate (FHR) in 
early pregnancy. 
Result 
FHR did not significantly change after oral misoprostol (P>0.05). All 
fetuses were alive at the second ultrasound examination. 
Conclusion 
A single oral dose of 200jig misoprostol does not appear to cause terminal 




響。硏究方法：對四十例孕齢7 - 1 5周的正常婦女每人給予2 W ^米索前 
列醇，服藥前及服藥后約1小時均進行陰道超聲檢查’測量其子宮動脈的 
搏動指數（ P �)，收縮與舒張血流速度的比値( S / D比値）和胎心率 
( F H R ) 。 結果表明：米索前列醇能顯著增加子宮動脈的阻力指數包 
括P I和S / D比値(兩者P均< 0.01 )，且此改變不被藥物弓丨起的腹痛所 
影響。另外，口服 lOO^ig米索前列醇約1小時沒有顯著影響胎心率（P 
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1. Introduction to thesis 
This chapter presents an overview of the thesis. Li addition, it introduces 
misoprostol and another commonly used prostaglandin analogue -gemeprost and 
discusses their use in Obstetrics & Gynaecology, especially current use of 
misoprostol for induction of labour with where there is a viable pregnancy and the 
implications for safety. 
1.1 Misoprostol 
1 • 1.1 Description and History of Drug 
Misoprostol is a prostaglandin Ei analogue. It was originally developed as 
a prophylactic against gastric and duodenal ulcers caused by aspirin and non-
steroidal anti-inflammatory drugs QS[SAID). This is because misoprostol can 
decrease gastric acid secretory and inhibit endogenous histamine release (Walt RP, 
1990). It also has mucosal cytoprotective effects (Anon, 1988). 
Misoprostol has a short elimination half time and relatively long duration of 
action, which is 21-35 minutes and 24 hours respectively. It is orally active and is 
easy to store. Furthermore, it costs less than another PGEi analogue-gemeprost. 
The details of pharmacology, pharmacokinetics and will be further discussed in 
chapter 3.3. 
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1.1.2 Current Use in Obstetrics and Gynaecology 
The potent uterotonic action of misoprostol, which was once an unwanted 
side effect，has become a new application ofmisoprostol in 0 & G in recent years. 
A brief review is shown below. Further discussion of the research shall be 
presented in chapter 3. 
1.1.2.1 Termination of Pregnancy (TOP) 
Misoprostol has been used in TOP alone and combination with 
methotrexate in first trimester (Creinin MD, Vittinghoff E, 1994). Misoprostol 
also has been used for abortion with mifepristone (RU 486) orally or vaginally in 
/ 
first trimester (el-Refaey H et al.,1995). Vaginal administration of misoprostol 
was more effective and better tolerated than oral administration for the induction 
of first-trimester abortion after the administration of mifepristone. Misoprostol, 
given alone, has been reported in TOP in second trimester (Jain JK, Mishell DR 
Jr, 1994). Misoprostol combined with mifepristone for TOP in second trimester 
has also conducted by el-Refaey H et al. (el-Refaey H，Templeton A, 1995). A 
study has compared the efficacy ofmisoprostol with gemeprost in second trimester 
TOP (el-Refaey H et al.，1993). There was no significant difference in the 
outcomes between the two groups. 
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LL2.2 Cervix Priming prior to Surgical Treatment ofPregnancy Failure 
Cervical laceration is a known complication of surgical evacuation of the 
uterus in TOP. Priming with misoprostol to soften and dilate the cervix can reduce 
mechanical force required and hence reduce the chance oftrauma (el-Refaey et al., 
1994). Edwards D et al. (1995) have studied 595 patients who were given 
misoprostol orally 30 to 60 minutes before surgical TOP. They reported that this 
facilitated the TOP. A lOOp.g dose ofmisoprostol was given to induce oflabour in 
women with late fetal death (BugaUio A et al., 1995). Successful induction was 
achieved in 81% with an induction-to-delivery interval of 13.8 hours. The authors 
noted few side effects apart from diarrhoea. 
1.1.2.3 Medical management of spontaneous abortion 
The current standard management for spontaneous abortion is surgical 
evacuation. However, in recent years, a number of studies have been shown that 
misoprostol can be effective in evacuating a proportion ofuteruses where there are 
retained products ofgestation (Chung T et al., 1994). 
1.2 Gemeprost 
Gemeprost, also known as cervagem and ONO-802, is 16,16-dimethyl-
trans-A^-prostaglandin Ei methyl ester. Its chemical formula is C23H38O5. It is 
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presented as a suppository and can be administered both by vaginal and 
intrauterine routes. Each suppository contains lmg gemeprost. 
Gemeprost is used for softening and dilatation ofcervix before transcervical 
intrauterine operative procedures in pregnancies in the &st and second trimester of 
gestation. Li this condition, one suppository is inserted into the posterior vaginal 
fornix three hours before surgery. It is also used for therapeutic TOP in the first 
and second trimester (Cameron IT, Baird DT, 1984). 
1.3 Doppler Sonography and Assessment ofBlood Velocity 
It is now possible to use Doppler sonography to study the flow velocity of 
most blood vessels in the human body. The uterine arteries are relatively 
accessible by both transabdominal and transvaginal sonography. Jn pregnancy, 
these vessels are relatively easily identified and measuring the flow velocities 
through the vessels can make an assessment of the resistance in the utero-
placental. This will be further discussed in chapter 4. 
1.4 Overview of Thesis 
hi recent years, misoprostol, which has been shown to have potent 
uterotonic actions comparable to gemeprost, has been increasingly used to induce 
labour in the third trimester of pregnancy where there is a viable fetus and where 
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the birth of a normal healthy baby was expected (Margulies M et al., 1992). It has 
been shown that misoprostol has similar actions in the first trimester as gemeprost. 
However, gemeprost is contraindicated in the third trimester because of the threat 
they pose for the fetus because they cause tetanic uterine contractions. 
In addition, misoprostol has been used for cervical priming in pre-labour 
rupture of membranes (ROM) at term QS[gai SW et al., 1996). The perinatal 
outcome were similar in the misoprostol group and placebo group. So the 
investigators concluded that misoprostol at a dose of 200^ig is effective for 
cervical priming in patients with pre-labour ROM at term. These results were 
consistent with those ofMarguiles et al. (1992). 
There have been two studies that have examined the impact of gemeprost 
on the pulsatility index ofuterine arteries during the first trimester pregnancy. The 
first study found that vaginal application of gemeprost in early pregnancy 
increases the vascular resistance ofuterine arteries and the effect is not affected by 
parity or gestational age and the change is similar in both uterine arteries (Joupplia 
P, Suomalainen-KOnig S, 1994). The authors recruited 21 patients and found that 
the mean value of pulsatility index increased significantly from 2.01(±0.53) to 
3.47(±0.85) before and after drug administration (^<0.001). Another group of 
investigators studied 67 pregnant individuals and found that gemeprost 
significantly increased the median value (from 2.4 to 8.5, P<0.01) of pulsatility 
index in the arteries of utero-placental circulation (including dominant uterine 
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arteries and subchorionic arteries, the intrachorionic area and arteries in the wall of 
the corpus luteum) in the first trimester and can induce fetal bradycardia (130 vs. 
163 bpm, p=0.003) and sometimes causes demise (Valentin L et al.，1995). Unlike 
the former study, Valentin et al. also studied the fetal heart rate, which reflects the 
well-being offetus. Both studies reached broadly similar conclusions. Gemeprost 
can increase pulsatility index of uterine arteries (UA-PI) in first trimester 
pregnancy. This may reflect that gemeprost may decrease uterine perfusion 
resulting in impaired oxygenation of the fetus, in tum causing fetal heart rate to 
low down and even fetal death. 
Misoprostol, like gemeprost, is a PGEi analogue. Potentially it may have 
the same adverse effects on the fetus. However, up to now, to the candidate's 
knowledge, there has been no published studies examining the impact of 
misoprostol on blood flow velocity of the uterine vessels. Compared with 
gemeprost, with its plasma elimination half-life is about 3-4 hours, the half life of 
misoprostol is shorter and it is also active orally. Whilst there are obvious 
advantages in introducing misoprostol for clinical use, the candidate notes that its 
use in late pregnancy, in the forni of clinical trials, has not been preceded by 
appropriate investigation of its effect on the fetus and the utero-placental 
circulation. This is ofrelevance since the use of misoprostol in late pregnancy, for 
example to induce labour, may be potentially dangerous to the fetus. 
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1.5 Aim of this Study 
Misoprostol has been advocated to induce labour in clinical Obstetrics for 
several years. However there has not been adequate research on its effect on the 
fetus and uteroplacental circulation. This study assesses the effects ofmisoprostol 
on the uteroplacental circulation in early human pregnancies. 
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2. Physiological and Anatomical Features ofPregnancy 
During pregnancy, there are exceptional changes in the cardiovascular 
system to meet the demands ofthe enlarging utems, the growing fetus and physical 
variation of the mother. This chapter briefly describes the changes that occur in 
the blood, the changes of the cardiovascular dynamics and the changes on the 
regional distribution of blood flow in uterus. Then it focuses on the blood supply 
to the uterus. The changes ofpelvic anatomy is also important to our study, it may 
be described with transvaginal sonography as a reference. 
2.1 Cardiovascular System Changes in Pregnancy 
2.1.1 Changes in the Blood 
The blood changes will be considered in blood volume, plasma volume and 
red cell volume separately. First the blood volume increases in pregnancy from 
4000ml to a maximum of5500ml by the 32nd week and decreases 200ml to 300ml 
thereafter, to fill the additional intra-vascular space caused by development of the 
placenta and the blood vessels. Furthermore, the plasma volume increases from 
the 10th week of pregnancy reaching a maximum of 3800 ml by the 32nd to 34th 
week. The total increase is about 1200 to 1500ml，which is 50% about the non-
pregnant plasma volume. There it remains to term. FinaUy the red cell volume 
increases in a linear pattem to term from 1400ml in the non-pregnant to 1800ml in 
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the last three months ofpregnancy. The increase peaks at 30%. Jn spite ofthis, the 
total increase in the red cell volume is proportionately less than the total increase 
in plasma volume. Li this way the concentration ofthe red cells in the blood falls, 
with a reduction in the haemoglobin concentration. This has been called the 
physiological anaemia of pregnancy, but it is a misleading term for the pregnant 
woman has a larger total haemoglobin than when non-pregnant. 
2,L2 Changes in Circulation 
Due to the high circulating levels of oestrogen, the stroke volume of the 
heart rises, and the heart rate also increases by about 15%. For this reason, the 
cardiac output increases by 30% to 50% in pregnancy, a rise from 5 litters per 
minute at the 10th week of pregnancy to 6.5 litters at about the 25th week for the 
purpose to deal with the increased blood volume and additional requirements for 
oxygen. The raised level is then maintained to term. 
The increased cardiac output, owing to the effect of oestrogen and 
progesterone, is balanced by a reduction in the peripheral resistance of the blood 
vessels and consequently the blood pressure is altered only minimally. 
The posture of the pregnant woman affects arterial pressure. Typically, 
blood pressure in the brachial artery is highest when sitting, lowest when lying in 
the lateral recumbent position, and significantly decreases when supine, sometimes 
referred to as the supine hypotensive syndrome. Usually, arterial blood pressure 
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decreases to a nadir during the second trimester or early third trimester and rises 
thereafter. 
Otherwise, in the supine position, the large pregnant uterus may compress 
the aorta sufficiently to lower arterial blood pressure below the level of 
compression (Bieniarz J and associates, 1968). This demonstrated that the usual 
measurement of blood pressures in the brachial artery does not always provide a 
reliable estimate of the pressure in the uterine or other arteries that lie distal to 
aortic compression. When the pregnant woman is supine, uterine arterial pressure 
is significantly lower than that in the brachial artery. 
2.1.3 The Distribution of Blood Flow in Uterus 
During pregnancy the uterus receives the greatest proportion of the 
increased blood flow. Recent evidence suggests that the flow increases from 75ml 
per minute at the 10th week ofpregnancy to about 500ml in the 35th to 50th week. 
This increased uterine blood flow is believed to be essential for normal fetal 
growth and nutrition and for the avoidance of matemal hypertensive 
complications. At the moment of uterine systole, blood is forced under pressure 
into the choriodecidual space from the endometrial arteries, and spurts through the 
intervillous lake to reach the chorionic plate. The stream loses velocity, surrounds 
and cascades over frond-like villi, allowing an exchange of nutrients and waste 
13 
products to take place before it drains away through the endometrial veins in 
uterine diastole, to be replaced by a further spurt with the next systole. 
2.2 Blood Supply to Uterus 
The vascular supply of the uterus is derived basically from the uterine and 
ovarian arteries. The uterine artery is a main branch of the internal iliac artery, 
which enters the base of the broad ligament, and makes its way medially to the 
side of the uterus. Jn so doing, it crosses anterior to the side of the ureter at the 
point 2 cm lateral to the cervix, hnmediately adjacent to the supra-vaginal portion 
of the cervix, the uterine artery is divided into two main branches. The smaller 
cervico-vaginal artery supplies blood to the lower portion of the cervix and the 
upper portion of the vagina. The main branch turns upward and extends thereafter 
as a highly convoluted vessel that traverses along the margin of the uterus; a 
branch of considerable size extends to the upper portion of the cervix and 
numerous other branches penetrate the body of the uterus. Just before the main 
branch of the uterine artery reaches the oviduct, it divides into three terminal 
branches: fundal, tubal and ovarian. The ovarian branch of the uterine artery 
anastomoses with the terminal branch of the ovarian artery; the tubal branch makes 
its way through the mesosalpinx and supplies part of the oviduct; and the fundal 
branch is distributed to the uppermost portion the uterus (Figure 2-1). 
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Figure 2-1 Vascular Supply ofthe Uterus 
;lo,p,ianti^^^^^^^^^^^^^__^^^^^^^^^^^^^erine^ Q j ^ S ^ ^ 5 ) 
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Branches of the uterine artery, the arcuate arteries, extend inward for a third 
of the thickness of the myometrium and encircle the uterus giving supply to the 
anterior and posterior walls. The radial arteries arise from the arcuate arteries and 
at right angles toward the uterine cavity. As these vessels enter the endometrium, 
they become the spiral arteries that undergo cyclic changes during the menstrual 
cycle. Approximately 100 spiral arteries connect the matemal circulation to the 
intervillous space during pregnancy. These vessels result in a tenfold increase in 
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the blood flow, which is required to catch up with the metabolic requirements of 
the fetus and placenta. 
The ovarian artery, a direct branch of the aorta, enters the broad ligament 
through the infimdibulo-pelvic ligament. At the ovarian hilum, it is divided into a 
number of smaller branches that enter the ovary. The main stem of the ovarian 
artery traverses the entire length of the broad ligament very near the mesosalpinx 
and makes its way to the upper portion of the lateral margin ofthe uterus, where it 
anastomoses with the ovarian branch ofthe uterine artery. 
2.3 Pelvic Anatomy in Early Pregnancy via Transvaginal Sonography 
Transvaginal sonography provides greater resolution of the pelvic organs 
than the conventional transabdominal sonography in early pregnancy. Jn this 
section, the normal anatomy of the uterus, ovary, and other adnexal and pelvic 
structures will be described as they would appear with transvaginal sonography.. 
2.3.1 Uterus 
Examination of the uterus begins with its presentation in long axis. One 
can easily find the endometrium, which is typically, echogenic to be the landmark 
for evaluation. 
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When the endometrium is identified in long axis, the sagittal and transverse 
plane can be obtained. The uterine size (length, width and depth) can be measured 
about from 7x4x3 cm^ to 8x5x4 cm^ in non-pregnant state. 
The volume of endometrium may be measured its long axis by the anterior-
posterior (AP) width and transverse dimension. The thickness ofthe endometrium 
will change flowing the menstrual cycle. It is 4 to 8 mm and 8 to 12 mm as well 
as showing the hypoechoic inner layer in the proliferative phase and periovulatory 
separately. During the secretary phase, the endometrium is from 8 to 14 mm and 
is significantly echogenic. When the women come to postmenopausal stage, their 
uterus decreases in size and measure only 4 to 6 mm in long axis. 
As the cervix becomes proximal to the probe under transvaginal 
examination, the image of cervix is not as clearly depicted as the rest ofthe uterus. 
Jn this condition one can withdraw the probe into the vagina and the image of the 
cervix can be obtained. 
Li early pregnancy, the uterus increases in size and the gestational sac, 
which appears as a 'double ring, in early first trimester, may be seen at the sagittal 
and transverse plane. The sac presents as a thick echogenic ring surrounding a 
sonolucent center, which is full of amnion fluid. The bilaminar embryonic disc 
and yoUc sac may be seen. However the yoUc sac can only be seen from the 5 to 12 
or 14 week. Otherwise the embryonic cardiac activity can be seen from 
approximately 5.5 weeks from last menstrual period. 
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2.3.2 The Adnexa 
The ovaries are beside the uterus and located along the pelvic sidewall. 
However in transvaginal sonography ovaries are typically situated anterior to the 
o 
internal iliac vessels. The size of an ovary is approximately 3x2x2 cm in long 
axis, AP and transverse dimensions separately. Nevertheless it is altered with the 
patient's age and phase of follicular development. An ovary can become twice as 
large in volume while it contains a mature follicle. 
The normal fallopian tube cannot be routinely visualised by transvaginal 
sonography due to its small size and serpiginous way. Occasionally one can 
identify the tube as an echogenic structure expanding from the uterine comu 
toward the ovary. Its diameter is only 6 to 10 mm in a coronal plane. 
2.3.3 Other Pelvic Structures 
Directing the beam posteriorly may identify the pouch ofDouglas. A small 
amomit of fluid can be seen in the cul-de-sac in normal physiologic circumstances. 
The presence of significant amounts of fi:ee fluid suggests a haemorrhage or 
purulent condition. The appearances of the round ligaments are similar to a non-
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3. Prostaglandins and Analogues 
Natural prostaglandins (PGs) are intimately involved in reproductive 
functions such as implantation and initiation of labour. PGE2 and PGF2a are the 
naturally occurring PGs. 
3.1 Natural Prostaglandins 
PGs are a series of enzymatic metabolites or peroxidating products of 
polyunsaturated (essential) fatty acid, especially contain C-20 carbon 
polyunsaturated fatty acid which has a special term "eicosanoids." The major 
natural source of eicosanoids is arachidonic acid. PGs were first identified by von 
Euler in 1935 to characterise the blood pressure lowering and smooth muscle tone 
modulating acidic lipids from human seminal fluid in prostate gland. They have 
been found throughout the body including the central nervous system, adrenals, 
liver, kidney and gut, where they are both humoural and neurotransmitter 
functions. 
3.2 The Source ofPGs in Reproductive Organs ofWomen ' 
In the non-pregnant state, the endometrium is the main source of PGs 
whereas in the gravid uterus, the amnion, decidua and placenta all have a high 
synthetic capacity. Otherwise, PGs can be synthesised by platelets and many 
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white blood cells including macrophages, neutrophils, mast cells and some T cells, 
skin and stomach and there is growing awareness of its role in lymphoid cells. 
The major natural prostaglandin, PGEi is present in significant amounts in human 
seminal fluid. 
PGEi has numerous biological activities such as modification of smooth 
muscle tone, adrenergic transmitter release, glandular secretion and platelet 
function as well as the inhibitory action on polymorphonuclear cells and immune 
response. 
3.3 PGs Synthesis and Metabolism 
PGs are synthesised on demand from precursor arachidonic acid (AA) by 
the action of phospholipases. Then AA is metabolised through the 
cyclooxygenase pathway to produce endoperoxides, PGG2 and PGH2, or by 
lipoxygenase toward leukotriene synthesis. The cyclic endoperoxides are unstable 
so are rapidly converted to primary PGs (PGD2, PGE2 and PGF2a) or via 
thromboxane or prostacyclin synthetase to thromboxane A2 and prostacylin (PGI2) 
respectively. The latter intermediates have short biological haLf-lives of 40 
seconds and 3 minutes, and are converted into their stable products TXB2 and 6-
0x0 PGFia (Figure 3-1). 
There are three PGE-type prostaglandins: PGEi, PGE2 and PGE3. They are 
synthesised from three unsaturated fatty acids, 8,11,14-eicosatrienoic acid. 
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5,8,11,14-eicosateraenoic acid (arachidonic acid) and 5,8,11,14,17-
eicosapentaenoic acid respectively (Gr^k K et al., 1981). 
Figure 3-1 Metabolic Pathway ofNatural Prostaglandins 
PHOSPHOLffroS 
)r 
^ ^ _ i 2 ^ AA 
LEUKOTRIENES 
COX \f 
^ ^ _ ^ ^ PGG2/PGH2 \ ^ ^ ^ 
TXA, / \ Pffl2 
TSB, / \ 6oxoPGFia / . \ 
PGF20c PGE2 PGD2 
The arachidonic acid cascade, illustrating the major uterine prostaglandin 
biosynthetic pathways. Lox = lipoxygenase. Cox = cyclo-oxygenase. AA = 
arachidonic acid, TX = thromboxane, PGI2 = prostacylin. 
3.4 PGEi Analogue: Misoprostol 
PGEi analogues have been produced with similar structure to PGEi. They 
have greater metaboUc stabiHty and hence greater activity when compared to the 
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natural compounds. There are 3 common PGEi analogues, gemeprost (other 
names: ONO-802, Cervagem), misoprostol (Cytotec) and sulprostone QSfalador). 
3.4.1 Misoprostol 
Misoprostol, DL-Methyl-11 oc- 16-dihydroxy-16-methyl-9-oxoprost-13E-en-
l-oate,.was originally developed as a prophylactic against peptic ulceration in 
patients taking long term non steroidal anti-inflanmiatory drugs. Its chemical 
formula is C22H36O5. It is a synthetic prostaglandin Ei methyl ester analogue. 
Misoprostol in the Cytotec tablet form also contains hydroxypropyl 
methylcellulose 2910, microcrystalline cellulose, sodium starch glycolate and 
hydrogenated castor oil. 
3.4.1.1 Pharmacology 
Misoprostol is rapidly de-esterified to misoprostoic acid and intact 
misoprostol cannot be detected in plasma or urine. Misoprostoic acid may be 
detected in urine and plasma by radioimmunoassay (RJA). Jn man, misoprostol is 
rapidly absorbed, extensively metabolised and excreted. Approximately 80% of 
an oral dose is absorbed within 1.5 hours following administration. Peak levels of 
misoprostoic acid, the chief metabolite, occur within 12 to 30 minutes and 
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disappear with an elimination half life of 21-35 minutes (Foote EF et al.，1995). 
Excretion is prolonged in renal failure. 
Misoprostol has major antisecretory effect mediated by the direct effect on 
the parietal cells of the stomach and mucosal cytoprotective properties on the 
stomach and duodenum. Divided daily oral doses of 1600 ^igms have been 
reasonably tolerated apart from gastrointestinal discomfort. It has also been used 
vaginally in doses of up to 1,600 ^igms in TOP without unacceptable side effects 
(BugaUio A et al., 1995). 
3.4.1.2 Adverse Side Effects 
The most conunon side effects are gastrointestinal; diarrhoea, cramp like 
abdominal pain and flatulence are dose dependent and occur in 10% of patients 
given the usual dose of 800 i^gms per day (Walley TJ, 1993). Nausea and 
headache have also been reported. There are no known potentially hazardous drug 
interactions. 
3.4.1.3 Toxicology 
Dogs given massive overdoses (9 mg.kg"^) develop tremors, mydriasis and 
diarrhoea. There is no known mutagenic potential. Large doses can lead to 
gastric hyperplasia in animals but this reverts to normal once misoprostol is 
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stopped. There is one report of a woman at a gestation of 31 weeks ingested a 
large amount of misoprostol and trifluoperazine (Stelazine). Manifestations of 
toxicity included hypertonic uterine contraction with fetal death, hyperthermia, 
rhabdomyolysis, hypoxaemia, respiratory aU<alosis, and metabolic acidosis (Bond 
&VanZee, 1994). 
3.4.1.4 Misoprostol in Obstetrics & Gynaecology 
ln Obstetrics & Gynaecology, up to recently, it has been mainly used in 
therapeutic TOP in combination with an antiprogestogenic agent, mifepristone. A 
summary of the current uses of misoprostol and the other major PG analogue, 
gemeprost is shown below. 
3.4.1.4.1 To Induce Abortion in First and Second Trimesters 
The first application in 0 & G of PGE! analogues was to induce abortion 
and to apply its cervix-dilating action in second trimester (Sakmoto S et al., 1982). 
ln this study the investigators used gemeprost by way of a vaginal suppository. 
Thereafter, for TOP, some investigators have used oral mifepristone (RU486) in 
combination with vaginal gemeprost in first trimester (Rodger MW et al., 1987; 
UK Multiceiiter trial, 1990) and others have used vaginal misoprostol only in the 
second trimester (BugaUio A et al., 1993). 
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Misoprostol has been used in TOP alone and combination with 
methotrexate in first trimester (Creinin MD, Vittinghoff E, 1994). Sixty three 
women were recruited for this study and were treated with either methotrexate 
50mg per square meter of body surface area plus misoprostol 800^g or the same 
dose of misoprostol given alone. The misoprostol dose was repeated 24 hours 
later in case of abortion had not occurred. It was considered successful if the 
pregnancy ended without requiring a surgical procedure. They found complete 
abortion occurred in 14 (47%) of30 patients in misoprostol alone and 28(90%) of 
31 patients treated with methotextrate and misoprostol. They concluded 
methotrexate and vaginal misoprostol were more effective than misoprostol alone. 
Misoprostol also has been used for abortion with mifepristone (RU 486) 
orally or vaginally in first trimester (el-Refaey H et al.,1995). Two hundred and 
seventy women were given mifepristone 600mg. If expulsion of the conceptus did 
not occur, a dose of misoprostol 800^ig was given orally or vaginally. Expulsion 
of the conceptus without the need for a surgical procedure occurred in 95% of the 
women who received misoprostol vaginally and in 87% of women who received 
orally (^<0.05). Ninety three percent of the women receiving misoprostol 
vaginally had abortions within four hours, as compared with only 78% of the 
women receiving the dmg orally (^<0.001). Vaginal administration ofmisoprostol 
was more effective and better tolerated than oral administration for the induction 
of first-trimester abortion after the administration of mifepristone. Moreover, 
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researchers using misoprostol in combination with mifepristone in first trimester 
have reported complete abortion rates in excess of 90% in the first trimester (Jing 
XPetal.,1995). 
Misoprostol, given alone, has been reported in TOP in second trimester 
(Jain JK, Mishell DR Jr, 1994). Fifty-five women were include in the study. The 
efficacy and safety of 200^ig misoprostol intravaginally every 12 hours and 20mg 
dinoprostone (PGE2) intravaginally every 3 hours has been compared. The rate of 
successful abortion within 24 hours was 81% (22 of 27 women), compared with 
89% (25 of 28 women) with misoprostol The mean interval from treatment to 
abortion was 10.6 hours with dinoprostone and 12.0 hours with misoprostol. The 
rate of complete abortion was 32% for dinoprostone and 43% for misoprostol. 
The side effects such as pyrexia, uterine pain, vomiting and diarrhoea were more 
frequent in the women receiving dinoprostone than misoprostol. The authors 
concluded that misoprostol was at least as effective as PGE2 for TOP in second 
trimester but with fewer side effects. 
Misoprostol combined with mifepristone for TOP in second trimester has 
also conducted by el-Refaey H et al. (el-Refaey H, Templeton A, 1995). Seventy 
women were pre-treated with mifepristone. Abortion was achieved in 97% of 
cases. The mean induction abortion time was 6.4 hours. The authors reported that 
there were no significant differences between vaginal or a combination of vaginal 
and oral administration. They recommended that following pre-treatment with 
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mifepristone, misoprostol was the prostaglandin ofchoice to induce abortion in the 
second trimester. 
The clinical efficacy of misoprostol and gemeprost for second trimester 
TOP has been examined (el-Refaey H et al., 1993). Sixty women were allocated 
into two prostaglandin regimens following pre-treatment with mifepristone 600 
mg. The first was given misoprostol 400^ig orally followed by gemeprost vaginal 
pessary 1 mg. The second was only gemeprost vaginal pessary 1 mg. There was 
no significant differences in the outcomes between the two groups. 
3.4.1.4.2 Cervix Priming prior to Surgical Evacuation of Uterus 
Cervical laceration is a known complication of surgical evacuation of the 
uterus in TOP. Priming with misoprostol to soften and dilate the cervix can reduce 
mechanical force required and hence reduce the chance of trauma. Since Sakmoto 
S et al. (1982) demonstrated that PGEi analogue, gemeprost, could be used to 
soften the cervix, studies have been conducted into the clinical utility of gemeprost 
and misoprostol for cervical dilation to facilitate first trimester TOP (Welch C, 
Elder MG, 1982; BugaUio A et al.，1994, el-Refaey H et al.，1994). 
Edwards D et al. have studied 595 patients who were given misoprostol 
orally 30 to 60 minutes before surgical TOP. They reported that patients given a 
total dose of 600^ig misoprostol were more likely (22%) to have cervices which 
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were easy to dilate than those receiving 400jiig of misoprostol (Edwards at al., 
1994). 
3.4.1.4.3 Medical Management of Miscarriage 
The earlier diagnosis of miscarriage by sonography has become more 
common and more conservative methods of uterine evacuation have been used. 
The current standard management for spontaneous abortion is surgical evacuation. 
However, in recent years, there have been a number of studies that have shown 
that PG analogues can be effective in evacuating a proportion of uteruses where 
there are retained products of gestation (Chung T et al., 1994). Jn a study of 132 
patients with retained products of gestation proven on TVS, gemeprost vaginal 
suppositories every 3 hours was able to empty the uterus in just under 50 % of 
cases. The same authors conducted another 2 studies using misoprostol (Chung 
TK et al, 1995, 1996) and found that misoprostol given orally was able to empty 
uteruses which has retained products of gestation by TVS in about 50-67 % of 
cases. Oral misoprostol has been used to treat missed abortion and brighted ovum 
(el-Refaey H et al, 1992). Some researchers have used sulprostone (PGE2 
analogue) and misoprostol to manage incomplete or inevitable abortion (Henshaw 
RC et al, 1993). 
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3.4.1.4.4 Liduction of Labour with Dead Fetus 
The first use of misoprostol for labour induction in stillbirth was reported 
by Mariani-Neto et al. in 1987. They studied 20 patients with gestation of 19-41 
weeks who presented with in-utero fetal death. Four hundred i^g of misoprostol 
was administered orally every 4 hours until delivery occurred. They reported that 
all dead fetuses were delivered successfully with a mean induction-to-delivery 
interval of 9 hours and 12 minutes. 
BugaUio A et al. in Maputo used vaginal misoprostol suppositories as an 
alternative to IV oxytocin for induction of labour with late fetal death (BugaUio A 
et al., 1995). Li this study, 156 women were enrolled and the induction-to-
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delivery interval in misoprostol group was shorter than in oxytocin group with 
Bishop's score <6，>6 or with intact membranes. Successful rate of induction 
reached 81% of misoprostol-treated women at a dose of 100 jixg or less. 
3.4.1.4.5 Liduction oflabour 
Misoprostol has been used for labour induction in viable state (Margulies M 
et al., 1992; Sanchez-Ramos L et al., 1993). The first had two studies ~ a dose-
fmding study and a comparative trial of misoprostol and oxytocin. The former 
study determined that misoprostol doses required averaged 162 jixg and 188p,g for 
patients with gestation age 28-36 weeks and more than 36 weeks respectively. 
The latter study was a randomised controlled trial comparing 50 jiig misoprostol 
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given intravaginally with IV oxytocin in 64 patients whose labours have been 
induced. The authors concluded that misoprostol is effective in the induction of 
labour atid there were few matemal side effects and no apparent adverse effects 
on the new-bom. 
Li second study, the investigators compared misoprostol administered 
intravaginal with IV oxytocin in 129 patients and demonstrated that intravaginal 
administration of misoprostol safely and effectively induced labour _ while 
minimising the expense associated with IV oxytocin infiision. Excessive uterine 
contractions occurred more frequently in patients in the misoprostol group but did 
not increase the risk of adverse intrapartum or perinatal outcomes. However, the 
sample size ofthis study was two small to be confident of detecting a difference in 
perinatal and intrapartum outcomes ifone exists. 
3.4.2 The Potential Dangers ofPGEi analogues 
Misoprostol has become more popular in 0 & G because of its low cost, 
convenient storage. However, its use in the induction of labour should be viewed 
with some caution at present 
There have been some reports about the use of misoprostol in labour-
induction causing excessive uterine contractions. However, apparently this did not 
increase the risk of adverse intrapartum or perinatal outcomes (Sanchez-Ramos L 
et al., 1993). Li this study, continuous electronic fetal heart rate monitoring 
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(including an intrauterine pressure catheter and scalp electrode). Margulies M et 
al. who studied 56 patients found that no adverse effects on the fetus or baby were 
observed. However, they observed systole more frequently in misoprostol group 
compared to the oxytocin group, but no fetal distress was associated with this 
condition in either groups. However, in this study, there was no universal 
continuous fetal monitoring. 
Misoprostol has been compared with intravenous (IV) oxytocin for the 
induction oflabour. Sixty four subjects with a singleton pregnancy were recruited. 
Thirty-three patients were given 50p,g misoprostol and 31 were given intravenous 
oxtocin. Success was defined as the woman going into labour. A 79% successfixl 
rate was found in the misoprostol group compared to 62% in the oxytocin group. 
One patient was delivered by caesarean section because of fetal distress in 
misoprostol group and 3 in the oxytocin group. 
Misoprostol has been used for cervical priming in pre-labour rupture of 
membranes (ROM) at term O^gai SW et al., 1996). Eighty patients were recruited 
and randomised to receive 200^ig misoprostol or 50 mg vitamin Be orally. If the 
patient did not go into labour 12 hours after oral medication with either 
misoprostol or vitamin Be, intravenous oxytocin infusion was started. The study 
found that the proportion ofpatients requiring oxytocin induction was lower (15%) 
in the misoprostol group than in the placebo group (51%) (P < 0.001). The 
perinatal outcomes were similar in the two groups. So the investigators concluded 
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misoprostol at a dose of 200p.g is effective for cervical priming in patients with 
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4. Doppler Sonography and Parameter Measurements 
The principles of ultra-sonography and Doppler apparatus will be discussed 
be low�This chapter will focus on how many and what kinds of commonly used 
methods ofblood flow measurement, as well as how to measure the blood velocity 
of the utems. Both continuous waves Doppler (CWD) and pulsed waves Doppler 
(PWD) have been used in the investigation of the UA. As the waveforms of UA 
are influenced by the site where the waveforms are obtained, as well as other 
factors such as the hormone, the resistance and diameter of the vessel etc., this 
chapter will also try to explore what the effects of those factors and the 
components of the waveforms are, as well as to demonstrate the waveform 
changes ofuterine arteries in the whole pregnant state. 
4.1 The Principles ofUltrasound and Doppler Sonography 
4.1 • 1 The Basic Principles of Ultrasound 
Ultrasound is a mechanical pressure wave. Its frequency is inaudible to the 
human ear and is usually beyond 20 to 20,000 cycles per second (Hz). The 
frequencies used in medical diagnosis are generally between 1 and 15 Megahertz 
(MHz). Diagnostic ultrasound used in 0 & G is usually between 3 to 7.5 MHz. 
Ultrasound has the same characteristics as sound, which is frequency, wavelength, 
amplitude, intensity, and propagation speed. When it passes through the different 
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boundaries in different angles, it has the phenomenon such as reflection, refraction 
absorption and scattering. 
The generation of ultrasound waves is based on the behaviour of the 
piezoelectric effect of certain materials, such as resins, crystals, or ceramics. An 
electronic voltage is generated while a crystal is compressed. It is the so called 
'piezoelectric effect.' Reversibly the application of a voltage through a crystal may 
induce compression or expansion inside. That is why electrical stimulation on 
piezoelectric materials can induce mechanical deformation, which can produce 
waves at ultrasonic frequencies. This phenomenon also operates in reverse: the 
echoed mechanical waves generate electrical signals, which can be recorded and 
analysed. 
Most crystals do not possess the property of piezoelectricity and the most 
important natural crystal possessing this property is quartz. It has been used in 
ultrasonic generators for many years but now it has been replaced in medical 
devices ahnost completely by synthetic ceramic crystals, barium titanate and lead 
zirconate titanate (PZT), for these have better mechanical properties and are easier 
to fabricate compared to quartz. 
When ultrasound pulses are transmitted into the tissue interface, a returning 
pulse or echo is generated to the point with different acoustic impedance. The 
average speed of sound passed through the soft tissue is uniformly calculated at 
1,540 meters per second. Then we can calculate the distance to the source of the 
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returning echoes. The intensity ofthe echo determines the brightness ofthe dot at 
that point on the screen. To create an updated imaging, which is the ‘real-time, 
imaging, the frame rate must be greater than the flicker-fusion rate of the eye， 
which is about 15 cycles per second or greater. This is considered adequate. 
According to the display of returning echoes, the techniques most used in 
clinic practice are: A-Mode (Amplitude mode), B-Mode (Brightness mode), M-
Mode (Motion mode) and Doppler type. 
4.1.2 Principles ofDoppler Sonography 
The Doppler principle is that when energy is reflected from a moving 
boundary, the frequency ofthe reflected energy varies in relation to velocity ofthe 
moving boundary. That is the Doppler effect described by Austrian physicist -
Christian Johann Doppler in 1842 (Doppler JC, 1842) and verified in 1845 by 
Dutch mathematician - C.H.D. Buys Ballot in a famous raikoad engine experiment 
(Fleischer AC et al., 1994). 
Li clinical use, the transmission and receiving sources are stationary and the 
change in path length results fi:om movement of the target either toward or away 
from these transducers. Li studies of blood flow, the moving column of blood 
within the studied vessels is the target. The red blood cells acted as scatters reflect 
the ultrasound beam. The frequency of sound reflected offmoving blood cells are 
altered to the sound emitted from the transducer on the velocity ofthe blood. 
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From the equation (showed inFigure 4-1), the change of frequency is 
known as the Doppler frequency shifts and is dependent on the moving object and 
the angle between the insonation beam and the direction of motion. If the beam's 
angle of insonation is known and the frequency shift can be determined, from the 
above equation we can convert to velocity ofblood flow. 
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Figure 4-1 Doppler equation, obtained from the Doppler frequency shift in vessels, 
relations to angle ofinterrogation. 
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where 
Fo = the frequency ofthe emitting source in cycles/s 
V = the velocity of blood flow 
cos 0 = the cosine ofthe angle ofinsonation 
C = the velocity of sound in tissue 1540 m/s 
AF = the difference in frequency between the emitted and 
returning sound 
Fr =the returned frequency 
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4.2 Doppler Mode 
There are three types of Doppler ultrasound used in modem diagnostic 
equipment. They are continuous wave Doppler, pulsed wave Doppler, and two-
dimensional colour flow mapping. 
4.2.1 Continuous Wave Doppler Lnaging 
Li this system a single transducer either transmits or receives the 
ultrasound signals. There are two piezoelectric elements within the transducer: 
one continuously transmits while the other continuously receives reflected echoes. 
Li such way the transmitted beam and the area of reception of echoes overlap. A 
continuous wave system will receive all Doppler-shifted waves from the reception 
zone but is unable to distinguish the site of origin ofthe echo signals. It is widely 
used in fetal heart rate monitoring, as well as in the Doppler assessment ofuterine-
umbilical blood flow. 
4.2.2 Pulsed Wave Doppler Systems 
Unlike continuous wave Doppler system, in this system ultrasound beam is 
transmitted in a pulsed fashion, and when not transmitting, the same crystal serves 
as a receiver for returning echoes. Current pulsed Doppler machines are of the 
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duplex type, which allows the same transducer to ultrasonically guide placement 
of the sample volume over the desired vessels and assess Doppler shift signals 
indicating flow velocity. 
4.2.3 Colour Doppler Sonography (CDS) 
Colour flow sonography involves the addition of colour to the ultrasound 
image to indicate direction of blood flow. Flow toward the transducer is 
represented by the colour red while flow away from the transducer is presented the 
colour blue. This flow information is then superimposed on the two-dimensional 
real-time images to form the complete colour Doppler sonogram. So it offers a 
new method to study circulation. 
The calculation of the blood velocity is shown in Figure 4-1. As can be 
seen, it is independent of the angle of insonnation, which allows for 1 source of 
possible error to be eliminated. 
4.3 The Ltistrument ofDoppler Sonography 
Sonography originated in the 1940s，but application in 0 & G began in 
1958. Later, Barber FE and others in 1974 successfully combined real-time 
sonography and Doppler to direct the Doppler beam more accurately. 
A sonographic system basically consists the following four sections: 
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1. A chief equipment that is an electronic signal processing unit with controls 
for power output and has the fimction of receiving and magnifying the 
electronic signal. 
2. A transducer (also called probe) with the piezoelectric crystals in it so as to 
change the electrical signal to ultrasound wave and verse visa. It comes in a 
variety of shapes and sizes. Some of the more common types are 
cylindrical, flat, perivascular, aspiration, and multi element transducer 
arrays. 
3. A gray scale unit to adjust the contrast and brightness ofthe image. 
4. A screen to record the images permanently. 
A Doppler ultrasound unit usually connects with an ultrasound scanning 
system and creates both high resolution images of internal blood vessels and the 
simultaneous values of blood flow velocity within them. Table 4-lwill illustrate 
the components of a Doppler ultrasound unit: 
Table 4-1 Components of a Ultrasound Machine 
Transducer Central Unit Output 
A. Transmitting crystal(s) Frequency changes detected A. Visual 
(Constant Frequency) 1. Oscilloscope screen 
2. Strip Chart 
B. Receiving Crystal(s) B. Audible Sounds 
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It is clear that based on the ultrasound system, a Doppler ultrasound unit 
may add several output formats: audible sounds, waves on an oscilloscope screen, 
or a tracing on a continuously moving paper chart. 
4.4 Resistance Lidices - S/D, PI and RI 
A waveform is the Doppler signal displayed on the monitor produced by 
and representing the Doppler shifts created by circulating red cells during a cardiac 
cycle. If Doppler signals produce a shift toward the transducer, an upward 
displacement of the baseline will display on the monitor while those signals 
producing a shift away from the transducer will display as a downward shift from 
baseline. 
‘ \ 
The most commonly used indices are systolic flow velocity /diastolic flow 
velocity ratio (S/D ratio), resistance index, and pulsatility index (PI) as shown 
below in Figure 4-2. � 
-i ： •' 
These three indices are indeg^dent of the incident angle as cos 9 in both 
“ r 
u^  U(-, the numerator and denominator c&efel out and do not need to measure the 00 '>, u^  ^ 
V »• 广 
diameter of the vessel. According to this benefit, clinicians usually like to use 
these indices to detect the resistance of vessels, especially in Obstetrics because 
the vessels studied are often too small to measure accurately and too tortuous to 
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Figure 4-2 Quantitative Methods ofWaveform Analysis 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^ W^RW5WWPB^ T^^^^^^ H^^ R^^5(^R^ f^r*^^^ s^^^  /L aa]R _^  S m H H H H H 9 B ^ U H H H H H I Mean^ Pulsatihty Index 
i ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H ^ ^ ^ ^ ^ | and 1975) 
^ ^ H ^ ^ ^ ^ ^ H (or S/D 
I V ^ ^ ^ p ;^^^^||!丨~^^^| (Stuart et al 1980) 
| ^ ^ n ' j | ^ H . i ; ' ' 4 ^ ^ | ^ ^ = Resistance Index 
v H B ^ j H H p ( S ; : 4 ^ m ^ (Pourcelot 1974) 
- • ^ ^ ¾ ^ ,^^^H^>'W^- ™ A - Peak systolic flow 
r^ i^.*nr":Py%^>^ -^ “ .51¾&>¾>:.'^ -¾ B - End diastolic flow 
mHlimillljllllllllllllllllllllllllHllllim Mean - Mean I 
determine the angle of insonation (for example, umbilical artery or uterine artery). 
However, these indices can be affected by fetal breathing (Lidik JK, Reed KL, 
1990), fetal heart rate abnormalities (Reed KL et al., 1987), and fetal 
movements(van Eyck J et al.，1985). Therefore the A/B ratio, PI and RI should be 
measured during the periods of fetal apnoea. 
Some work has been done to assess other features of the waveform such as 
acceleration time, deceleration time, volume flow, etc. However it shows no 
advantage over the previously mentioned three indices. 
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4.5 Flow Measurement ofUterine artery 
4.5.1 Sampling Sites and Waveforms 
There are four different parauterine vessels which are sample sites for 
measuring the flow velocity waveforms. They are external iliac artery, uterine 
artery near its origin, arcuate branches near the placenta bed (Schubnan H et al., 
1986) and the subplacental vessels (Tmdinger BJ et al.,1985). The subplacental 
vessels and arcuate vessels have the highest diastolic frequency and have the 
lowest ratios. The external iliac vessels have no end-diastolic velocity but a 
prominent notch because of the high resistance. Otherwise, the main uterine 
arteries have a higher systolic component. Sometimes a significant notch is seen 
in the first trimester. UA waveforms obtained from the site as it crosses the 
external iliac artery are the same as the site near its origin from the internal iliac 
artery (Oosterhof H, Aamoudse JG, 1992). One can easily locate the main uterine 
artery using the colour Doppler imaging while it crosses the external iliac artery. 
Arcuate, radial and spiral arteries have high sampling bias, and are extremely 
difficult to reproduce and do not reflect the whole uteroplacental circulation 
(Bewley S et al, 1989). Livestigators usually use the main uterine arteries to 
reflect the total resistance to blood flow in the utero-placental circulation. 
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4.5.2 Waveform Components 
The total flow waveform is divided into two parts: a pulsatile component 
and a steady component. The pulsatile flow waveform is subdivided into an 
outgoing wave and a reflected wave. The former generates through the contraction 
of heart and propagates towards the peripheral vessels. The latter reflects the 
wave that bounces back to the heart from the utero-placental bed, so its waveform 
is inverted to the outgoing waveform. Combination of the outgoing and reflected 
waves produces the total pulsatile component ofthe flow waveform. Attaching the 
steady flow to the pulsatile component will create the total flow waveform 
(Adamson SL et al., 1989). If we know the cross-sectional area of the blood 
vessel, then the velocity can be calculated from the total flow waveform. 
4.5.3 Identification ofthe Main Uterine Arteries 
The main uterine artery is the segment ofthe artery arising from the internal 
iliac artery to the lateral aspect of the cervix. There, it divides into the uterine and 
vaginal branches. Both colour Doppler and pulsed Doppler can be used to identify 
the uterine artery (Kurjak A et al., 1991). The details of identification ofthe UA 
will be discussed in section 6, 
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4.5.4 UA Waveform Changes in Normal Pregnancy 
Li first trimester, the compliance of UA rises initially and then falls. 
Consequently, a prominent diastolic component can be detected as early as the 
fifth week of gestation. Following this, the resistance index gradually decreases 
from the sixth to the twelfth weeks (Merc^LT et al., 1989). So the waveforms 
obtained from UA, occurring in the way of elevated S/D ratios and reduced end-
diastolic velocities, presents with a dicrotic notch in the systolic deceleration slope 
(Schubnan H et al., 1986) (Figure 4-3). The dicrotic notch was thought to be a 
reflection of a reflected wave of high amplitude returning from a utero-placental 
bed while the vascular resistance is elevated (Mo LY et al., 1988). 
Coming to the second trimester, the vascular resistance decreases as 
gestation progresses with a progressive increase in the cross-sectional area of the 
uterine artery, as well as the morphologic changes of the spiral arteries in the 
placental bed� 
After 24 to 26 weeks of gestation, the early diastolic notch should 
completely disappear, so as the difference of S/D ratios between placental sites to 
non-placental sites (Schubnan H et al., 1986). Any abnormality such as elevated 
resistance index and the diastolic notch appearing after 24 to 26 weeks may 
indicate preeclampsia or small-for-gestational-age fetuses (Tmdinger BJ et al., 
1985). 
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Figure 4-3 The Doppler waveform from left uterine artery shows the notch in the 
systolic deceleration slope in early pregnancy. 
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Li the first 24 hours postpartum, the S/D ratio increases and the blood 
velocity remains high. By the second day postpartum, both S/D ratio and PI 
increase and the diastolic notch reappears until the sixth puerperal week. After 
that, the resistance indices start to rise again until the third puerperal month 
(Thoresen M, Jarlis W, 1988). 
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4.5.5 Factors Affecting the UA Waveforms 
The placental site can affect the UA waveforms. For example, compared 
with the uterine artery at the point where it crosses the external iliac artery, a 
significantly lower pulsatility index (PI) value was found in the arcuate arteries 
near the placenta bed (OosterhofH, Aamoudse JG, 1992). 
Otherwise, some authors have developed a computer modelling to study the 
factors that determine velocity waveform shape. They found that the utero-
placental vascular resistance, uterine arterial diameter and the blood pressure aU 
have the effect on the uterine arterial velocity waveform (Mo et al,1988; Adamson 
SL,1989). If utero-placental resistance increase, the systolic/diastolic velocity 
(S/D) ratio and pulsatility index of the waveform wiU increase. However, a 
dicrotic notch wiU appear. If the radius ofthe uterine artery is reduced, the S/D 
ratio and PI can increase. In this case, however, a dicrotic notch is not produced. 
On the other hand, if the mean arterial pressure in the uterine artety increases, 
there is aknost no change in S/D ratio or PI. 
Moreover, the hormones, oestrogen and progesterone, also affect the uterine 
circulation. This may be due to the oestrogen receptors occurring in the wall of 
human uterine arteries (Perrot-Applanat M et al., 1988). Those patients with 
absent ovaries, their baseHne estimation show narrow systoUc Doppler flow waves 
with a pulsatility index of 5.2±0.4 (mean±SEM). The elevation of plasma 
oestradiol (E2) and progesterone can induce a profound decrease in the vascular 
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resistance and an uninterrupted flow signal during the diastolic interval (de Ziegler 
Detal . , 1991). 
4.5.6 Uterine Artery Resistance in Normal Pregnancy and Labour 
Several authors have studied the changes of the uterine blood flow, usually 
using the resistance indices from the non-pregnant state to the early pregnancy and 
until term in normal situation. This chapter will review the above items separately. 
4.5.6.1 Uterine Artery Resistance in Normal Pregnancy 
Doppler ultrasound provides a non-invasive approach of measurement of 
blood flow velocity. Since the ratio ofpeak systolic to diastolic flow velocity was 
used as a measure of downstream resistance (Gosling RG, King DH, 1974), a 
method of recording flow velocity-time waveforms of the uterine artery using 
pulsed Doppler ultrasound has been reported (Campbell S et al., 1983). 
There have been some investigations on the resistance indices of uterine 
artery in normal pregnancy, hi first trimester, the resistance index shows a gradual 
weekly decrease, with significant differences before [(S-D)/S = 0.83+09] Vs after 
the 9th week [(S-D)/S = 0.72±0.10] (Merc^LT et al., 1989). This study enrolled 
twenty-five early singleton pregnant women from 7 to 13 weeks from the last 
menstrual period and found that a highly resistant systemic vessel with an elevated 
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systolic peak and reduced end-diastolic flow. Otherwise, a notch is present in the 
systolic deceleration slope. 
Trudinger BJ et al. in 1985 had studied twelve normal pregnancies from 20 
weeks to delivery and concluded that there was a small decrease S/D ratio with 
gestational age indicative of a decreasing flow resistance (Trudinger BJ et al.， 
1985). 
Changes in uterine blood flow during human pregnancy, which from non 
pregnant state to term, have been explored. Thaler et al. studied 24 patients and 
found that S/D ratio declined from a mean of 5.3 in the non-pregnant state to mean 
of2.3 near term (Thaler I et al., 1990). 
Li conclusion, resistance to flow decreases in the utero-placental-umbilical 
circulation as gestational age increase in normal pregnancy mainly due to the 
forward diastolic flow increasing with gestation age. The changes in flow are 
reflected in the decrease ofthe Doppler indices: S/D ratio, RI, PL The decreasing 
in these indices means the falls in the resistance of blood vessel in the utero-
placental-mnbilical circulation. The increasing in blood flow may have the 
advantage for the fetus. 
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4.5.6.2 Uterine Artery Resistance during normal labour 
It is important to understand the normal changes ofuterine artery resistance 
in labour. It may help us to be aware ofthe abnormal condition and what it will be 
potentially harmful to the fetus. 
Li labour, the frequency of uterine contractions rises and the intrauterine 
pressure increases. Fleischer A et al. have studied uterine and umbilical artery 
velocimetry during normal labour (Fleischer A et al., 1987). They have observed 
12 patients throughout the three stages of labour and found that the uterine artery 
waveforms changed during contraction. Before labour, the changes in uterine 
artery velocity waveforms consist of the loss of diastolic notch and a progressive 
decrease in the S/D ratio (Schubnan H et al., 1986). During the uterine 
contractions in labour, the spiral arteries are being constricted in proportion to the 
intensity of the contraction. The impact of these changes on the uterine artery 
waveforms is a progressive fall ofthe diastolic blood flow velocity. The degree of 
changes is related to the intensity of the uterine contraction. During the period of 
contraction, the end-diastolic velocity even reaches zero when the intrauterine 
pressure is over 35 mmHg. Where there is intrauterine pressure greater than 60 
mm Hg, no diastolic notch was detected. The authors concluded that the end-
diastolic component is primarily determined by changes in the arcuate and spiral 
arteries. However, they did not report the changes of the values of resistance 
indices, during three stage on the uterine arteries. 
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Maymon R et al. have studied the changes in uterine artery velocity 
waveforms during the third stage of labour (Maymon R et al., 1995). They 
observed three phases of the third stage of labour and found S/D ratio and PI of 
uterine artery were 2.14 士 0.53 and 1.28 士 0.37 respectively in latent phase, 2.53 士 
0.53 and 1.28 士 0.37 respectively during a contraction and, 2.20 士 0.34 and 0.91 士 
0.20 respectively in expulsion phase (p<0.05). They concluded that the uterine 
artery Doppler flow velocity waveforms reflected by a high resistance flow 
according to the increase ofresistance due to the uterine contractions. Up to now, 
the candidate is not aware of any studies which has examined the changes of 
resistance indices ofUAs during the first and second stages oflabour. 
4.5.7 Doppler Measure ofFetal Heart Rate 
The variation of fetal heart rate can reflect fetal status in the uterus, 
especially during delivering. It has developed many methods for monitoring the 
fetus, such as fetal ECG from matemal wall or ultrasonography. 
There is little information to describe the normal ranges of FHR in first 
trimester. The vagus nerve may play an important role in the progress of FHR. 
From 15th gestational week to term, FHR reduces with advancing gestational age 
in normal pregnancy (Stuart B et al.，1984; Robinson S, 1991). FHR at 18 weeks 
is about 148±5 bpm. There are no differences in fetal heart rate between the sexes 
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at 18 weeks gestation. However, by 36 weeks the boys had rates which were 4.4 
beats lower than those ofthe girls (95% CI is 0.8-8.0, P=0.02) (Robinson S, 1991). 
At term, the normal ranges of FHR is 120 to 160 beats per minute (bpm). 
Less than 120 bpm is defined as bradycardia and more than 160 is tachycardia. 
Fetal bradycardia may be related to hypoxia, while fetal tachycardia is possible 
due to fetal distress. Fetal breathing, dmgs, fetal movement (rest or activity) may 
lead to FHR variation. To use Doppler measuring FHR, one can calculate the time 
interval between two cardiac cycles. 
4.6 Sonography in Estimation of Gestational Age 
The widespread dissemination of sonography has enabled routine 
visualisation of the pregnancy at the first antenatal visit. With the endovaginal 
sonography (TVS), we are able to precisely date the pregnancy; to directly 
diagnose ectopic pregnancy or at least to suspect it. So diagnosis can precede 
rupture, and allow management to be more conservative and less destructive; to 
definitively diagnose its failure before spontaneous passage, or to identify the 
completed abortion from incomplete and missed abortion. Li such way, the 
medical or non-surgical treatment is possible (Mansur MM，1992; Rulin MC et al., 
1993; Haines CJ et al., 1994). 
Li the first trimester pregnancy, gestational sac and crown-rump length 
(CRL) can now established the gestational age. The most accurate prediction of 
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menstrual age would be obtained by measuring the gestation sac among 5-6.5 
weeks. After 6.5 weeks, there is an alternative measurement, the CRL (Robinson 
HP et aL, 1975; Drumm JE, 1977). Bi-parietal diameter (BPD) and femur length 
(FL) are the common used parameters in the second and third trimester 
measurements. However, in the late second and third trimesters, increasing error 
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5. Research Protocol 
This chapter describes the research protocol in detail. 
5.1 The Ethics 
This study described in this thesis was carried out in accordance ofthe code 
of ethics described in the Declaration of Helsinki and last amended in 1989 ( 
World Medical Association Declaration, 1989). It states that it is the mission of 
the medical doctor to safeguard the health of the people. His or her knowledge 
and conscience are dedicated towards the Mfibnent of this mission. The purpose 
of biomedical research involving human subjects must be to improve diagnostic, 
therapeutic and prophylactic procedures and the understanding of the aetiology 
and pathogenesis ofdisease. 
This aim of the study was to determine the effects of misoprostol on the 
resistance indices of the utero-placental circulation via an examination of the 
blood flow velocity of the uterine arteries (UAs). This research is worthwhile 
because it can yield useful information on the impact of the administration of a 
small dose of misoprostol on the utero-placental circulation. Misoprostol may 
have potential dangers to the fetus in late pregnancy where it is now being used to 
induce labour where there is a viable pregnancy. 
Misoprostol has a low incidence of side effects and are mainly dose 
dependent and most are gastrointestinal in nature. The fact that administration of 
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this drug may be dangerous in these cases is accepted because these women had 
been admitted for TOP where the fetal welfare is not a point of consideration. The 
main concern in this case is the safety of the medication to the mother. Adverse 
effects such as diarrhoea were thought to be acceptable because misoprostol is of 
therapeutic value for the subjects involved in the study as it acts as a priming agent 
for the cervix prior to TOP. This therapeutic value is independent of the research 
being carried out. 
This study was conducted with the subject being fully conscious at all 
times. She was also aware that a portion of the interventions was purely research 
in nature atid that she is at liberty to withdraw from the study at any time. They 
were specifically counselled that should they refuse to participate in the study that 
this refusal will not compromise their clinical care. 
This research was approved by the Ethics Committee of The Chinese 
University of Hong Kong. Before recruitment, all subjects were counselled about 
the research protocol and gave both verbal and written consent (appendix I or II). 
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5.2 Apparatus 
A Doppler ultrasound system with a 5.0 MHz curvilinear transvaginal probe 
(Aloka UST-980P-5，Aloka Co., Ltd) was used. The apparatus, Aloka Echo 
Camera SSD-2000 (Aloka Co., Ltd), was equipped with only non-coloured pulsed 
Doppler. The high-pass filter was set at 50 or 100 Hz . The apparatus used is 
shown in Figure 5-1. 
Figure 5-1 Apparatus Used in Study 
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5.3 Drug and Dosage 
Subjects who had no any contradictions were given misoprostol 200p,g 
(DL-methyl-1 la-16-dihydroxy-16-methyl -9- oxoprost- 13E - en-l-oate; Cytotec, 
Searle) by oral administration. 
5.4 Research Protocol 
5.4.1 Subjects 
Subjects with a normal singleton intrauterine pregnancy of 7-15 completed 
gestational weeks were recruited for the study. All the subjects had been admitted 
for legal, surgical TOP. The inclusion criteria were the presence of normal 
singleton intrauterine pregnancy. Those subjects were excluded from the study 
when they had: 
1. Asthma 
2. Heart disease 
3. Glaucoma 
4. Known allergy to prostaglandins 
5. History of epilepsy 
All study subjects recruited were counselled and signed a specific consent 
form (Appendix I or II). 
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A before and after administration of misoprostol effect on the resistance 
indices was measured. The difference between these 2 measurements (delta) was 
used to measure the effect ofmisoprostol. The hypothesis was that the delta value 
would deviate significantly against the expected zero. The candidate 
acknowledges that this method has no proper control group and that these changes 
observed cannot be compared against a proper control group of women who had 2 
TVS examinations without any active intervention or placebo in between. 
5.4.2 Transvaginal Scan 
Then the first ultrasound scan was performed. Before the scarming, the 
subjects were prepared lying in a supine position on the examination table with 
their knees bent. The following features were noted on each scan: 
1. Ifthe gestational sac is single 
2. If the fetal pole is present 
3. If the embryo or fetus is viable 
4. What is the CRL or BPD of the fetus 
5. If the adnexa of uterus is normal 
6. If there is free fluid in POD 
All subjects who had an abnormal pregnancy such as missed abortion, 
blighted ovum, mole pregnancy, ectopic pregnancy and multiple pregnancies were 
excluded from the study. 
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5.4.3 Parameters Measured 
Following the assessment of the pregnancy, using the Doppler ultrasound 
apparatus, the study parameters were measured. Those were FHR, S/D ratios and 
PI of left or right main uterine arteries (LS/D, RS/D, LPI, RPI) (Figure 5-2to 
Figure 5-4). 
The UA were examined at the level of the internal os as the artery 
approaches the uterus laterally (Figure 5-5). The internal os is visualised in the 
sagittal plane. The probe is then turned into the transverse position and then 
angled upwards towards the long axis ofthe uterus. The vascular bundles are then 
easily visualised and pulsations that can be seen in real time help identify the 
uterine arteries. The characteristic blood flow velocity waveforms were then 
obtained by placing the Doppler gate over the identified area. Mtially, a number 
of examinations were done with the aid of colour Doppler facility. However, this 
machine became unavailable before the commencement of the study proper. 
Nevertheless, by using the method described above, it was relatively easy to 
visualise the uterine arteries and obtain the characteristic wave forms. 
For Doppler measurement colour Doppler was not available but the 
anatomical landmarks were used. This was based on the identification of the UA 
waveform which a characteristic notch existed in the systolic deceleration slope as 
mentioned in 4.5.5 before 20 to 24 weeks gestation，as well as a high systoHc 
62 
velocity�This typical appearance can help us to exclude the waveforms of arcuate 
arteries and subplacental vessels. 
Where possible, 3 consecutive cycles of wave forms were used for analysis 
of the left and right uterine arteries. An attempt was made to take three 
consecutive and discrete readings on the right side main uterine arteries were 
obtained. The examinations were documented on videotapes and on hard copies. 
Figure 5-2 The Picture Shows the Pattem of FHR 




Figure 5-3 The Picture Shows the Measurement of S/D ratio 
I^HII^H ——MW 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H ^ ^ m ^ ^ m n HRH  ¾¾¾¾¾(¾¾¾¾!^¾!! 
m^^^^^^^^^^^m 
MKlfOiM_,if i i f^^^^Mi—ii^^^^i^MjMP^SMMliiM^iaaa^^ ^^^H|^ ^H 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ p p p p j | j p p p p i l l l B B i P P l i i P t f ^ B B : ^ ^ ^ i i i ^ ^ — ^ g t o ^ ^ — i ^ — l ^ ^ l t e a l ^ ^ 
65 
5.4.4 Misoprostol 
After the &st scan, each subjet was given 1 200jiig tablet of misoprostol. 
One hour later the second scan was performed. This time the FHR, LPI, RPI, 
LS/D, RSfD were again measured. Furthermore, the side effect of the drug may 
also be recorded simultaneously. After that, the patients proceeded to TOP. 
Summary ofthe study protocol is showed below (Figure 5-6). 
Figure 5-6 Summary ofthe Study Protocol 
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5.5 Data analysis 
All statistical analyses were carried out on a personal computer (PC) using 
Statistical Package for Social Sciences - SPSS software for Windows (Version 
6.0). Wilcoxon Signed-Rank Test, one of the non-parametric methods which do 
not require samples from normally distributed populations, was used for testing 
differences between before and after administration of misoprostol in whole group 
and all subgroups. The Mami-Whitney test was used to determine the differences 
between pain group and no-pain groups. P value of less than 0.05 was taken as 
statistically significant. A Bonferoni correction factor, which was use for making 
multiple (m) pairwise comparisons, 0.05/m as the confidence level for each 
pairwise comparison. As this study the cases were divided into three groups 
(whole group, pain group and no pain group), P<0.02 was adopted as a correction 
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6. Results 
6.1 The Patients' Characteristics 
Forty-one pregnant women seeking termination of pregnancy (TOP) were 
recruited for the study. One was excluded because of asthma. Data from 40 cases 
were available for analysis. Both left and right UA were observed in as many 
subjects as possible. Thirty-seven pairs of data of both on RS/D and RPI were 
obtained while twenty-two and twenty-one pairs of data on LS/D and LPI were 
obtained respectively. 
The mean age of women was 28.3 士 8.6 years old. The mean gestational 
age was 10.8 士 1.8 weeks. The mean parity was 1.5 土 1.3. The mean ofprevious 
spontaneous abortion was 1.0 士 0.0. The mean of TOP was 1.1 士 0.5. Ten of 
them were less than 9 weeks gestation. Twenty-three were more than 9 weeks and 
less than or at 12 weeks gestation�Seven were at greater than 12 weeks gestation� 
Twelve were nulliparous and 28 were parous. The characteristics of these subjects 
are show in Table 6-1 below. 
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Table 6-1 Characteristics of Study Subjects 
J u u L L u u u u L L u u u L u u u u u u u u ~ L j ^ m n n n n n m n t i M _ m M J » 3 g i " ^ l « _ « _ l W J O C T M X » A H _ 1 * C T f 1 . ” , ^ , , . _ " > n r T y n T y » f « r > 0 0 " ~ * » » ^ » " * * * * » * » » * * * • _ _ “ _ - r w x W O O O O t * > C _ : w . i n n n n W O l l * > t W P P P O O O O O 
_ttW>«X»UU<>»OCW<OCCC«CC«COTCTX<03CTXPOOCCTOTOOCOTOOOOCOOOCCCgPOCCCOTOOOOOOCgr»CKCCWOtfOOOOOOCCOTOOOOCOCCrCTCTWOOOOCCOLK4iW>W>a&ii<W>4M^M^HJwiK_W>W><W_W_<w»~»_»~«_i*uii«_"_»~«~«^，、^,_, • • • • • - • 
Characteristic Mean SD Range 
Age (Years) 2 ^ ^ 15-42 
Gestation (Weeks) 10.8 1.8 7-14 
Gravida Number % 
1 10 25 
2 7 17.5 
>=3 23 57.5 
Parity 
0 12 30 
1 9 22.5 
2 9 22.5 
> = 3 1 0 2 5 
Previous Spontaneous Abortion 
0 37 92.5 
1 3 7.5 
Previous Therapeutic TOP 
0 26 65 
1 13 32.5 
2 0 0 
>二 3 1 2 . 5 
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6.2 The Mra-observer Error 
The coefficient variation of UA-S/D and UA-PI can be calculated by 
choosing the 'CFVAR' function, in ‘Compute’ variable from the 'Transform' 
menu on the SPSS software. The percentage of mean coefficient variations is the 
observer error. Li this study, the same examiner conducted all measurements. 
Therefore the intra-observer error ofUA-PI is 8.3% and UA-S/D is 11.1%. 
6.3 Results of Study 
6.3.1 Effect of Misoprostol on the S/D ratio of Both Uterine Arteries 
As mentioned before, there were twenty-two and thirty-seven pairs of data 
on LS/D and RSD respectively. These were combined to total forty pairs of data 
on UA-S/D for analysis. The average changes between after and before UA-S/D 
values is 2.85(±0.57). Eight subjects showed decreasing on UA-S/D. 
The UA-S/D increased significantly (P<0.01) from 6.99 (± 0.48) to 9.84 (± 
0.61) after administration of misoprostol (Figure 6-1) shows the individual change 
of before and after in the whole group of UA-S/D. As can be seen，from first 
quartile to maximum of the study population, the change of UA-S/D between 
before and after was greater than zero. That means the study population, taken as 
a whole, had increase of UA-S/D after taking misoprostol. There were two 
probable outliers from the chart. One is 11.49 and the other is 14.69. These two 
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outliers may be due to the bias of the examiner. The change was statistically 
significant in both the group of women who had abdominal pain at the time of the 
second TVS (p=0.01) and those who did not have abdominal pain (p=0.01). This 
is summarised in Table 6-2. 
Table 6-2 UA-SA) before and after Administration ofmisoprostol 
S/D ratio 
Groups n Mean (SEM), both side UA After - Before p value 
Before After Mean (SEM) 
Whole group"""40 6.99 (0.48) 9.84 (0.61) 2.85 (0.57) <0.01 
Pain 22 6.50 (0.48) 8.92(0.79) 2.42 (0.81) 0.01 
No pain 18 7.58 (0.67) 10.96(0.90) 3.38 (0.80) 0.01 
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Figure 6-1 UA-SA3 changes before and after Misoprostol Administration 
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6.3.2 Effect ofMisoprostol on the PI ofBoth Uterine Arteries 
Twenty-one and thirty-seven pairs of data were collected on LPI and RPI 
respectively. They were combined to total forty pairs of data on UA-PI for 
analysis. The average changes between after and before UA-PI values is 
0.46(±0.09). There were eleven pairs of cases decreasing on UA-PI. 
UA-PI in both side uterine arteries also increased significantly (P<0.01) 
from 2.32 (土 0.10) to 2.78 (± 0.12) after misoprostol had been administered. 
Figure 6-2 shows the individual changes in the whole group of UA-PL From the 
chart, from first quartile to maximum of the study population, the change ofUA-PI 
was greater than zero. The change was statistically significant in both the group of 
the women who had abdominal pain at the time of the second examination 
(p<0.01) and those who did not had abdominal pain (p<0.01). Table 6-3 
summarises the individual changes ofUA-PI in the whole group and subgroups. 
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Table 6-4 Fetal Heart Rate before and after Administration ofMisoprostol 
Pusatility index 
Groups n Mean (SEM), both side UA After _ Before p value 
Before After Mean (SEM) 
Whole group~~40 2.32 (0.10) 2.78 (0.12) 0.46 (0.09) <0.01 ~~~ 
Pain 22 2.21 (0.14) 2.65(0.14) 0.44(0.11) <0.01 
No pain 18 2.45 (0.14) 2.93 (0.15) 0.48 (0.15) 0.01 
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Figure 6-2 UA-PI Changes (Bilateral) After Misoprostol 
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6.3.3 Effect ofMisoprostol on Fetal Heart Rate (FHR) 
The average changes ofFHR is 1.26(± 1.40). The minimum is —10 and the 
maximum is 16. There was a decrease seen in ten pairs of data while nineteen 
pairs showed an increase. However, there were no changes in ten pairs. 
There were no significant changes in FHR after misoprostol (P>0.05). 
None of the fetuses died. This is shown in Table 6-4. Figure 6-3 shows the 
individual change of before and after FHR. There are two extremes observed 
value. One is possible outlier and another is probable outlier. The former had an 
increase of 19 bpm while the latter has decreased by 34 bpm. These two observe 
mothers both had no abdominal pain, no vaginal bleeding or other discomforts. 
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Table 6-4 Fetal Heart Rate before and after Administration ofMisoprostol 
Fetal Heart Rate After - Before 
Groups n Mean (SEM) Mean (SEM) p value 
Before After (bpm) (P<0.05) 
Whole group 39 169.6 (1.28)~~170.8 (1.55) 1.26 (1.40) N S ~ 
Figure 6-3 Lidividual FHR Changes after Misoprostol 
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6.3.4 Left and Right UA-S/D 
Significant changes were found in the right UA-S/D in the group as a whole 
and in all subgroups (P all<0.01). Significant changes did not demonstrated in the 
left UA-S/D in the group as a whole and subgroups. This may have been due to 
insufficient cases. This is shown in Table 6-5and Table 6-6. 
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Table 6-4 Fetal Heart Rate before and after Administration ofMisoprostol 
Left S/D ratio 
Groups n Mean (SEM) After _ Before p value 
~ B e f o r e After Mean (SEM) 
Whole group ^ 7.40 (0.72)~~9.21 (0.82) 1.80 (0.80) NS(0.03) 
Pain group 12 6.53 (0.92) 8.00(1.03) 1.47(0.96) NS 
No pain group 10 8.44(1.10) 10.65 (1.25) 2.21 (1.39) NS 
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Table 6-4 Fetal Heart Rate before and after Administration ofMisoprostol 
Right S/D ratio 
Groups n Mean (SEM) After - Before p value 
~~Before After Mean (SEM) 
Whole group ^~~~7.16(1.09)~~10.26 (0.67) 3.10 (0.58) <0.01 ~ 
Pain group 20 6.51 (0.69) 9.21 (0.85) 2.70 (0.89) <0.01 � 
No pain group 17 7.92 (0.87) 11.49(1.02) 3.57(0.72) <0.01 
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6.3.5 Left and Right UA-PI 
The significant difference was found both in left and right UA-PI in the 
whole group (P=0.02 and P<0.01 respectively). However, in the subgroups, no 
significant changes were found in the left UA-PI whatever the women had 
abdominal pain or not (Table 6-7). Li the right UA-PI, only pain group had 
significant changes, as shown in Table 6-8. 
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Table 6-4 Fetal Heart Rate before and after Administration ofMisoprostol 
Left pulsatility Lidex 
Groups n Mean (SEM) After - Before p value 
Before After Mean (SEM) 
Whole group~~H 2.38 (0.17) 2.70 (0.18) 0.33 (0.14) Ko2~~~ 
Pain group 11 2.14 (0.27) 2.40(0.24) 0.25 (0.21) NS 




Table 6-4 Fetal Heart Rate before and after Administration ofMisoprostol 
Right Pulsatility Lidex 
Groups n Mean (SEM) After - Before p value 
Before After""" Mean (SEM) 
Whole group � 2.38(0.11)~~2.90 (0.12) 0.51(0.11) <0.01 ^ 
Pain group 20 2.26(0.15) 2.85 (0.18) 0.59 (0.15) <0.01 
No pain 17 2.53 (0.16) 2.95 (0.15) 0.41 (0.18) NS 
group 
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6.3.6 The relationship Between Subgroups 
There were no statistically significance ahnost in all parameters (UA-S/D, 
UA-PI, LS/D, LPI, RS/D, RPI) between pain and no pain group (p>0.05). 
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6.3.7 Side Effects of Misoprostol 
Side effects ofmisoprostol in this study mainly were abdominal pain (n=22, 
55%) and vaginal bleeding (n=16, 40%). Others included headache, nausea, 
vomiting, faint and dizziness. One patient had a rash (2.5%) on the back of her 
right hand. This is summarised in Table 6-9. 
Table 6-9 Summary of Side Effects after Administration ofMisoprostol 
Side Effect Number % 
Abdominal pain 22 55 
Vaginal bleeding 16 40 
Headaches 8 20 
Nausea and vomiting 5 12.5 
Faint 2 5 
Dizziness 1 2.5 
Rash 1 2.5 
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6.3.8 The Changes of UA-S/D and UA-PI According to Gestation 
The SfD ratio and PI, their standard error of mean were calculated for each 
gestational week before and after misoprostol Their relationships are shown in 
Figure 6-4 and Figure 6-5. They demonstrate that UA-S/D and UA-PI decrease as 
gestation increases. 
Figure 6-4 Change in UA-PI with Gestation and Misoprostol 
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Figure 6-5 Changes in UA-S/D in Relation to Gestation 
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7. Discussions and Conclusions 
7.1 Difficulties Encountered during Study 
Considerable difficulty was encountered initially during the work of this 
thesis. The candidate has had minimal experience doing TVS and in obtaining the 
resistance indices required in the study. The candidate spent abnost 6 months in 
learning to do a satisfactory TVS and obtain the data. Furthermore, obtaining 
consent was difficult, especially during the early part of the study. There was a 
general reluctance of subjects to partake in clinical experiments and in particular to 
undergo another TVS for purely research purpose. However, with increasing skills 
and experience, a satisfactory number was eventually recruited. 
There was an unforeseen problem with TVS. Unlike TAS, TVS is an 
invasive procedure. Whilst TVS is well tolerated for routine examination, it was 
apparent in some women that a prolonged examination, as required in this study, 
was difficult to endure. Consequently, it was not possible to obtain a complete set 
of data in all subjects due to subjects' discomfort. Fifteen examinations had to be 
terminated prematurely for this reason. This problem was compounded in a few 
cases by difficulty identifying the left uterine artery. This means that in 19 of the 
possible 80 measurements, no data was available. This may have compromised 
the ability of the data to demonstrate the hypothesised effect. However, 
significant differences were nevertheless observed although it is acknowledged 
90 
that in the analysis of the subgroups, failure to demonstrate significant differences 
may have been the result of inadequate numbers in the subgroups. 
In retrospect, the study was perhaps better done by TAS and colour 
Doppler. However, in the case of the colour Doppler, this equipment was not 
readily available for research. 
Misoprostoic acid, the active metabolite of misoprostol, reaches peak 
plasma levels about 30-45 minutes after oral administration. Hence, the choice of 
60 minutes to examine the UA flow velocity would appear to be a reasonable one. 
7.2 Results ofStudy 
Our results demonstrate a similar effect of misoprostol on the utero� 
placental flow velocity at the UA level to that found by Jouppila P et al. (1994) 
and Valentin L et al.(1995). That is: misoprostol also increases the resistance of 
UA in early pregnancy. 
Vascular PI and S/D ratio all are angle independent and we presume that 
predict they reflect the resistance of vessel. Elevated PI and SfD ratio mean the 
resistance in these vessels was increased. Because PI reflects vascular resistance 
in the smaller peripheral arteries distal to the point of measurement (Maulik D et 
al., 1992). UA-PI can also reflect the resistance in utero-placental and myometrial 
arteries. There are two possibilities to explain the raised vascular resistance after 
treatment with misoprostol. One may be the direct PGE-like effects on the uterine 
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vessels that lead to vasoconstriction. Another could be the increasing uterine 
tonus and contractions leading to the secondary vasoconstriction in the UA. The 
above two investigators who studied the effect of gemeprost on UA-PI could not 
identify which that is the important factor. In this study, we recorded which 
patient has abdominal pain and which did not have abdominal pain after the 
administration of misoprostol. We used abdominal pain as an index of uterine 
contraction. Nevertheless we noted that whether there was abdominal pain or not， 
the UA-PI and VJA-SfD increased after the treatment with misoprostol. However, 
pain is a poor parameter for measuring contractions. Furthermore, as we were 
using TVS, a prolonged examination was not acceptable to the patient. A 
prolonged examination may have been able to assess uterine contractions or a least 
change in uterine tone. Further studies involving other peripheral vessels，which 
are not influenced by myometriaI contractions, may help to solve this question but 
these will not reflect the resistance of the vessels in the utero-placental circulation. 
Raised UA-S/D and UA-PI may lead to decreased uterine perfusion in the 
utero-placental circulation. This may have resulted in a decreased blood flow to 
the uterus and may oxygenation of the fetus, and in extreme circumstances, causes 
fetal bradycardia or even fetal death (Valentin L et al.，1995). However, from the 
results of our research, we note that FHR was not affected by the treatment with 
misoprostol and aU the fetuses were stiU alive at the second ultrasound 
examination. It was interesting to note that 2 of the fetuses had substantial 
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changes. The significance of this is unclear because episodes of profound 
bradycardia are not uncommonly observed during routine sonographic 
examination. 
Elevation of UA-PI or UA-S/D may be due to the diastolic flow velocity 
decreasing after misoprostol. Valentin L et al. have studied gemeprost and 
measured the UA-PI over several contractions. They observed that the reversed 
diastolic flow velocity was usually seen 15-30 minutes after gemeprost was given 
and the diastolic velocities changed with uterine contractions, hi our study, only 
one reversed diastolic flow velocities was seen. This is illustrated in below in 
Figure 7-1. As far as we know, there have been no studies to compare the 
influence of misoprostol on UA-PI by local vaginal suppositories or by oral 
application. When given by the oral route, the systemic side effects are greater 
than vaginal suppositories (Hisslein P, 1992) and the vascular effect may greater 
than vaginal route. However, separating them will be difficult. 
The resistance indices decreased gradually as gestation increases and this is 
consistent with previous studies e.g., Schubnan H et al., 1986). The decreasing 
resistance indices enable greater perfusion of the utero-placental bed and enable 
the mother to meet the needs of the growing fetus. However, the effect of 
misoprostol in this relatively narrow gestational study window is probably 
consistent. 
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Figure 7-1 Change of the Waveform after Treatment with Misoprostol 
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Where the subgroup did not reach statistical significance was probably due 
> 
to the small number of cases in the individual subgroups. 
7.3 Lnplications 
We have documented that even in a small dose of misoprostol has a 
significant effect on the resistive indices ofthe utero-placental circulation. Li one 
case, there was even reversal ofdiastolic flow, a fmding generally considered to be 
disadvantageous to the fetus. In late pregnancy, the uterine vascular bed may not 
be as sensitive to the physiological vasoconstrictor effect such as PGI2, so the 
action ofmisoprostol in late pregnancy may be weaker than in early pregnancy. 
The range of dose ofmisoprostol, which the fetus can tolerate, has not been 
found yet. Margulies M et al. (1992) have repeated one tablet which each 
containing 50^ig through vaginal route, in a method of every 2 hours until 
satisfactory uterine activity was achieved, to induce labour in 33 patients and 
reported a 79% successful rate within 24 hours. There were few side effects on 
the mother and no obvious adverse effects on fetus or newbom baby. However, 
these studies are far too small to be able to detect changes in fetal distress and poor 
perinatal outcome. Further research is required into this area. The same authors 
have also performed a dose-fmding study and found that misoprostol dose required 
was between 162 i^g and 188 i^g. The maximum used was 600^ig, with the 
percentage of patients delivering within 8 hours of induction was 96% and 73% in 
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gestational age 28-36 or more than 36 weeks respectfully. The dosage and 
regimen of administration that carries the least risk for the fetus but is nevertheless 
effective has not been determined. 
7.4 Summary ofThesis 
The work ofthis thesis is a observational study examining the impact of the 
administration of 200 jigms of misoprostol on the resistive indices of the UA in 
early pregnancy. UA-PI and S/D ratios are simple resistance indices and 
independent on the angle of insomiation. This thesis also studied the influence of 
misoprostol on the fetal heart. 
The study has shown that misoprostol can significantly increase the 
resistance indices including PI and SfD ratio of uterine arteries Q><0.01). That 
means the resistance of uterine arteries rose after the administration of 
misoprostol, ln subjects who had lower abdominal pain after treatment with 
misoprostol, there has no difference compared with the no abdominal pain as both 
groups had increased UA-PI and UA-S/D. (p<0.01). There was no demonstrable 




Orally administered misoprostol has significant effects on the utero-
placental blood flow velocity whereas it has no effects on the FHR in early 
pregnancy. This thesis has show that the resistance indices of the utero-placental 
circulation are increased after misoprostol. This means that the circulation may be 
affected given the same perfusion pressure. Misoprostol therefore may present a 
hazard for the fetus even in low doses, perhaps independently of its abortive 
fimction. Misoprostol has been used for the induction oflabour where a live birth 
is expected. Li these circumstances the possible effect of the drug on the fetus 
should be monitored closely in view of the documented effect on the utero-
placental vascular resistance. 
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ppendix I Consent Form 
Misoprostol and Uterine Blood Flow Study 
Dear Madam, 
You are have a termination of Pregnancy tomorrow. As part of your care, 
you require transvaginal scan to confirm the gestation and to examine your adnexa' 
In addition, you will be given 1 tablet of misoprostol, which will make the surgical 
procedure easier to do because it will make your cervix softer. The drug 
misoprotol is a safe. 
We would like to do a second vaginal scan about 1 hour after the first scan. 
This second is for research and is not part of your clinical management. We ask 
you to help in this matter because we are interested in the effect of this drug, 
misoprostol, on the blood flow to you uterus. 




The Chinese University ofHong Kong 
Consent 
I, understand that I shall be given 
1 tablets of the drug misoprostol to assist in my operation. I also understand that 
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！ TELEGRAM • SINOVERSITY TELEX • 50301 CUHK HX FAX: (852) 2603 6958 
Our Reference ： FM/C/l3 
Your Reference ： 
4 M a y 1996 
Dr. Tony K.H. Chung 
Dept. of Obstetrics & Gynaecology 
CUHK . 
Dear Dr. Chung, 
I write to inform you that ethical approval has been given for you to engage in the project named below: 
Project Title: "Uterine artery blood flow and misoprostol” 
(ref. No. CRE-646) 
Investigator(s): Dr. Tony K.H. Chung, Senior Lecturer, Dept. ofObstetr ics & 
Gynaecology, CUHK 
Ms Angel Tse On Ki, MPhil. Student, Dept. of Obstetrics & 
Gynaecology, CUHK 
'j .j 
Location of Study: Prince of Waies Hospital 
Duration: : years 
Conditions by CUnical Research Nil 
Ethics Committee (if any): 
It will be much appreciated if the completion of the project will be reported to the Committee in 
due course. 
Yours sinc^peiy7"> 
i < f ^ 
Andrew Chan 
Secretary 
Clinical Research Ethics Committee 
.. 
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